Onegene Biotechnology

At Onegene Biotechnology, we are dedicated to making a significant impact on patients' lives by staying at the forefront of research and development. We are excited to share that DaeSeong Im, our Chief Technology Officer (CTO), invited to the Australia Biologics Festival (ABF) 2023, hosted by IMPAC .. We believe in building upon the work of the pioneers who came before us, and we are constantly striving to push the boundaries of multi-target drug development. Onegene Biotechnology is a preclinical stage biotech established in 2016 and headquartered in Suwon, South Korea. Our unique advantages lie in our expertise in dissecting disease microenvironments and combining chemistry and protein engineering for the best multi-specific mechanisms. Our flagship program, OGB21502, is a tetraspecific drug for NASH treatment, and we are also developing trispecific drugs for IPF and immuno-oncology. We believe that the next big step in treating complex, untreatable diseases will come from multi-modality drugs. Recently we hold a long-awaited workshop to celebrate a successful scale up of OGB21502 production.Our passionate and talented team devoted months of ..